CD8A and neoplasm: Additionally, CAFs may affect CD4+ T-helper (TH) lymphocytes, favoring tumor-promoting TH2 and TH17 responses, and inhibit CD8+ cytotoxic T-cell activation, function and survival [207,208,209,210].